{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-065185","form_type":"8-K","ticker":null,"cik":"0001832415","company_name":"Better Therapeutics, Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.862572+00:00","generated_at":"2026-06-07T23:29:49.177112+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Better Therapeutics CFO Mark Heinen resigns; CEO Frank Karbe takes over as principal financial officer","bullets":["CFO Mark Heinen resigned effective Nov 27, 2023, as part of expense reduction measures.","CEO Frank Karbe assumes principal financial officer duties; controller Leslie Miller becomes principal accounting officer.","Miller receives a base salary increase and annual incentive compensation upon appointment.","Measures include voluntary salary reductions by CEO and other executives to extend cash runway for AspyreRx.","Resignation not due to any disagreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-065185","json":"https://secwatch.observer/filing/0000950170-23-065185.json","markdown":"https://secwatch.observer/filing/0000950170-23-065185.md","text":"https://secwatch.observer/filing/0000950170-23-065185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/bttx-20231117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:29:49.177112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00de67a9ee","claim":"Mark Heinen resigned as Chief Financial Officer at Better Therapeutics, Inc..","evidence_excerpt":"On November 14, 2023, Mark Heinen notified Better Therapeutics, Inc. (the “Company”) of his resignation as the chief financial officer of the Company, effective November 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1aa235b44b","claim":"Frank Karbe was appointed as Principal Financial Officer at Better Therapeutics, Inc..","evidence_excerpt":"Frank Karbe, the Company's chief executive officer (\"CEO\"), will assume the duties of principal financial officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"31c376b494","claim":"Leslie Miller was appointed as Principal Accounting Officer at Better Therapeutics, Inc..","evidence_excerpt":"Leslie Miller, the Company's controller, will assume the duties of principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000095017023065185/0000950170-23-065185-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}